Oryzon Genomics SA
Oryzon Genomics SA (ORY) is a clinical-stage biopharmaceutical company based in Spain, specializing in the development of epigenetics-based therapeutics for the treatment of diseases with strong unmet medical needs. The company operates primarily in the biotechnology and pharmaceutical sectors, focusing on the development of drugs targeting histone demethylases, a key component in the regulation of gene expression. Oryzon's core products include its lead compounds iadademstat and vafidemstat, which are being investigated for the treatment of various oncology and central nervous system disorders, respectively.